Resverlogix Corpis A Biotechnology Company Based In Calgarycanadafounded In 2001It Specializes In Epigenetics And Is Dedicated To Developing Innovative Therapies For Chronic Diseasesthe Company Aims To Enhance Patientslives By Restoring Biological Functions Affected By Serious Illnessesparticularly Cardiovascular Disease The Lead Product Of Resverlogix Is Apabetalonean Epigenetic Drug Designed To Regulate Disease Related Epigeneticsapabetalone Is Currently Being Evaluated In A Global Phase 3 Clinical Trial Called Betonmacefocusing On Cardiovascular Diseaseassociated Comorbiditiesand Post Covid 19 Conditionsresverlogix Has Partnered With Eversana To Support The Commercialization Of Apabetalone In Canada And The United States Resverlogix S Common Shares Are Traded On The Toronto Stock Exchange Under The Ticker Symbol Tsx Rvxthe Company Actively Provides Updates On Its Financial Performance And Developments Through Its Investor Relations Section
